Sandoz Group AG SDZNY

Company Overview

Sandoz Group AG is a global pharmaceutical company specializing in generic medicines and biosimilars, operating within the broader healthcare and life sciences industry. The company focuses on developing, manufacturing, and commercializing cost-effective alternatives to branded pharmaceuticals after patent expiration, with the objective of improving patient access to essential treatments. Its primary revenue drivers are generic small‑molecule drugs and biosimilar versions of complex biologic medicines, serving hospitals, pharmacies, governments, and healthcare providers.

Sandoz traces its origins to 1886 in Basel, Switzerland, and for decades operated as the generics and biosimilars division of Novartis. In October 2023, Sandoz became an independent, publicly listed company following its spin-off from Novartis AG. Since becoming standalone, Sandoz has positioned itself as one of the world’s largest pure‑play generics and biosimilars companies, emphasizing scale manufacturing, scientific expertise in complex products, and a broad global portfolio as strategic advantages.